+41 91 682 20 40 info@elixi-int.com

Nerlynx, neratinib, a breast cancer medicine used to reduce the risk of the disease coming back in patients with early breast cancer who have had surgery.

Nerlynx is indicated for the extended adjuvant treatment of adult patients with early stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who are less than one year from the completion of prior adjuvant trastuzumab based therapy. It is intended for use only in breast…

Read More

Pfizer’s Herceptin (trastuzumab) biosimlar Trazimera has been approved by the European Comission.

Pfizer has announced the European Commission (EC) has approved TRAZIMERA,  a biosimilar to Herceptin  (trastuzumab), for the treatment of human epidermal growth factor (HER2) overexpressing breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.  This approval follows the recommendation from…

Read More

Third Novartis Phase III trial shows Kisqali (ribociclib) combination therapy significantly improves PFS in HR+/HER2- advanced breast cancer

Novartis has announced positive results from the third Phase III trial of Kisqali (ribociclib) in advanced or metastatic breast cancer. MONALEESA-3 showed Kisqali plus fulvestrant significantly prolonged progression-free survival (PFS) compared to fulvestrant alone in postmenopausal women with hormone-receptor positive, human…

Read More